The Liver Diseases Therapeutics Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Liver Diseases Therapeutics Market?
The market size for liver diseases therapeutics has experienced significant growth in recent years. It is projected to increase from $14.16 billion in 2024 to $15.23 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Liver Diseases Therapeutics Industry?
The Liver Diseases Therapeutics market is predicted to expand to $20.78 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.1%.
Download Your Free Sample of the 2025 Liver Diseases Therapeutics Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Liver Diseases Therapeutics Market?
The key drivers in the liver diseases therapeutics market are:
• Adoption of precision medicine approaches in liver disease treatment
• The innovation in RNA therapeutics
• Growing focus on fibrosis treatments and their development
• Increased patient advocacy, support groups and regulatory support for orphan drugs.
Global Market Segmentation: Identifying Major Liver Diseases Therapeutics Industry Segments
The liver diseases therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol-Induced, Liver Cancer
2) By Treatment: Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids
3) By End User: Hospitals, Ambulatory Surgery Centers, Other End Users
Pre-order the 2025 Liver Diseases Therapeutics Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Liver Diseases Therapeutics Market?
The key trends in the liver diseases therapeutics market are:
• The future of the Liver Diseases Therapeutics market is significantly influenced by precision medicine approaches and innovations in RNA therapeutics.
• There is an increasing trend towards the development of treatments for fibrosis and vaccines for hepatitis.
• The market will continue to see advancements in treatment for hepatitis C and emergence of novel therapies for liver fibrosis.
• The exploration of immunotherapies, adoption of telemedicine, and focus on nutritional interventions will become key trends shaping the future of the market.
Who Are the Top Competitors & Leading Players in the Liver Diseases Therapeutics Market?
Major companies in the liver diseases therapeutics market are:
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Novartis AG
• GlaxoSmithKline PLC
• Abbott Laboratories Inc.
• Pfizer Inc.
• Sanofi SA
• Johnson & Johnson Services Inc.
• Bayer AG
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Valeant Pharmaceuticals
• Watson Pharmaceuticals Inc.
• AstraZeneca PLC
• Gilead Sciences Inc.
• Endo International PLC
• Alnylam Pharmaceuticals Inc.
• Provectus Biopharmaceuticals Inc.
• Intercept Pharmaceuticals Inc.
• Conatus Pharmaceuticals Inc.
• CymaBay Therapeutics Inc.
• Viking Therapeutics Inc.
• Madrigal Pharmaceuticals Inc.
• NGM Biopharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Dicerna Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the liver diseases therapeutics market in 2024
